HealthCare Global Enterprises (HCG) announced a 13% increase in revenue for Q3 FY26, reaching ₹6,331 Mn. Adjusted EBITDA rose by 20% to ₹1,108 Mn, with margins expanding to 17.5%. The company highlighted its commitment to integrated cancer care and research. HCG’s CEO noted steady performance across the network despite seasonal softness.
Financial Performance
HealthCare Global Enterprises (HCG) has released its financial results for Q3 FY26, showcasing growth in revenue and profitability. Key highlights include:
- Revenue from Operations: ₹6,331 Mn, a 13% increase compared to ₹5,586 Mn in Q3 FY25.
- Adjusted EBITDA: ₹1,108 Mn, a 20% increase compared to ₹923 Mn in Q3 FY25.
- Adjusted EBITDA Margin: Increased by 98 bps to 17.5%.
- Adjusted PAT: ₹6 Mn.
Nine Months Performance
For the nine months ended December 31, 2025, HCG reported the following consolidated results:
- Revenue from Operations: ₹18,931 Mn, a 16% increase from ₹16,377 Mn in the corresponding period.
- Adjusted EBITDA: ₹3,458 Mn, a 20% increase from ₹2,893 Mn.
- Adjusted EBITDA Margin: Increased by 60 bps to 18.3%.
- Adjusted PAT: ₹216 Mn.
Strategic Focus
The company remains focused on delivering comprehensive cancer care through its network. Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, emphasized the company’s dedication to delivering the right treatment the first time with a focus on patient outcomes. HCG aims to strengthen leadership and continue growth both domestically and internationally.
CEO Comments
Dr. Manish Mattoo, CEO of HealthCare Global Enterprises Ltd., commented on the company’s Q3 performance, noting steady execution despite seasonal challenges. He highlighted resilient demand for high-quality oncology care across key modalities, driving scalability and margin expansion. The results underscore the effectiveness of the company’s operating leverage.
Source: BSE
